David L. Bilhartz

2.5k total citations · 1 hit paper
18 papers, 2.0k citations indexed

About

David L. Bilhartz is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, David L. Bilhartz has authored 18 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 4 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in David L. Bilhartz's work include Prostate Cancer Treatment and Research (9 papers), Prostate Cancer Diagnosis and Treatment (5 papers) and Sexual function and dysfunction studies (4 papers). David L. Bilhartz is often cited by papers focused on Prostate Cancer Treatment and Research (9 papers), Prostate Cancer Diagnosis and Treatment (5 papers) and Sexual function and dysfunction studies (4 papers). David L. Bilhartz collaborates with scholars based in United States. David L. Bilhartz's co-authors include Charles Y.F. Young, Benjamin T. Montgomery, Paul E. Andrews, L. Michael Glodé, Thomas Schuetz, Philip W. Kantoff, Donald J. Tindall, Wayne R. Godfrey, William L. Dahut and Michael S. Wyand and has published in prestigious journals such as Journal of Clinical Oncology, Biochemical and Biophysical Research Communications and The Journal of Urology.

In The Last Decade

David L. Bilhartz

18 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

2010 727 citations Philip W. Kantoff, Thomas Schuetz et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David L. Bilhartz United States	15	1.2k	741	524	432	307	18	2.0k
PR Carroll United States	7	659 0.5×	766 1.0×	175 0.3×	611 1.4×	414 1.3×	14	1.7k
Ann Koons United States	14	451 0.4×	450 0.6×	363 0.7×	533 1.2×	415 1.4×	27	1.7k
S Dirnhofer Switzerland	25	172 0.1×	738 1.0×	499 1.0×	503 1.2×	194 0.6×	64	1.8k
Maria Monne Italy	17	431 0.3×	541 0.7×	249 0.5×	628 1.5×	248 0.8×	38	1.5k
J Richard France	19	478 0.4×	1.2k 1.6×	102 0.2×	467 1.1×	283 0.9×	38	2.0k
Constantina Petraki Greece	25	356 0.3×	564 0.8×	96 0.2×	577 1.3×	330 1.1×	63	1.7k
Jena D. French United States	16	292 0.2×	668 0.9×	650 1.2×	294 0.7×	120 0.4×	27	1.7k
M Giai Italy	18	219 0.2×	460 0.6×	165 0.3×	474 1.1×	268 0.9×	33	1.2k
Christian Kersting Germany	22	294 0.2×	440 0.6×	140 0.3×	790 1.8×	295 1.0×	42	1.6k
Shin Ebara Japan	18	415 0.3×	383 0.5×	282 0.5×	684 1.6×	231 0.8×	65	1.6k

Countries citing papers authored by David L. Bilhartz

Since Specialization

Citations

This map shows the geographic impact of David L. Bilhartz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David L. Bilhartz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David L. Bilhartz more than expected).

Fields of papers citing papers by David L. Bilhartz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David L. Bilhartz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David L. Bilhartz. The network helps show where David L. Bilhartz may publish in the future.

Co-authorship network of co-authors of David L. Bilhartz

This figure shows the co-authorship network connecting the top 25 collaborators of David L. Bilhartz. A scholar is included among the top collaborators of David L. Bilhartz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David L. Bilhartz. David L. Bilhartz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

1.

Kantoff, Philip W., Thomas Schuetz, Brent A. Blumenstein, et al.. (2010). Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 28(7). 1099–1105. 727 indexed citations breakdown →

2.

Godfrey, Wayne R., Brent A. Blumenstein, Thomas Schuetz, et al.. (2009). 7002 Further analysis of a Phase II randomized controlled trial (RCT) of a poxviral-based PSA targeted immunotherapy in metastatic castration-resistant prostate cancer (mCRPC). European Journal of Cancer Supplements. 7(2). 406–406. 2 indexed citations

3.

Kantoff, Philip W., et al.. (2006). Randomized, double-blind, vector-controlled study of targeted immunotherapy in patients (pts) with hormone-refractory prostate cancer (HRPC). Journal of Clinical Oncology. 24(18_suppl). 2501–2501. 23 indexed citations

4.

Smith, Matthew R., Fairooz F. Kabbinavar, Fred Saad, et al.. (2005). Natural History of Rising Serum Prostate-Specific Antigen in Men With Castrate Nonmetastatic Prostate Cancer. Journal of Clinical Oncology. 23(13). 2918–2925. 377 indexed citations

5.

Polascik, Thomas J., Robert Given, Gary Karlin, et al.. (2005). Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. Urology. 66(5). 1054–1059. 35 indexed citations

6.

Benson, Ralph C., et al.. (1996). Treatment of Penile Fibrosis with Prosthetic Implantation and Flap Advancement with Tissue Debulking. The Journal of Urology. 156(2 Pt 1). 394–397. 16 indexed citations

7.

Knoll, L. Dean, et al.. (1996). A Randomized Crossover Study Using Yohimbine and Isoxsuprine Versus Pentoxifylline in the Management of Vasculogenic Impotence. The Journal of Urology. 155(1). 144–146. 19 indexed citations

8.

Fisher, Jack C., et al.. (1996). Treatment of Penile Fibrosis with Prosthetic Implantation and Flap Advancement with Tissue Debulking. The Journal of Urology. 156(2). 394–397. 15 indexed citations

9.

Knoll, L. Dean, et al.. (1996). A Randomized Crossover Study Using Yohimbine and Isoxsuprine Versus Pentoxifylline in the Management of Vasculogenic Impotence. The Journal of Urology. 155(1). 144–146. 11 indexed citations

10.

Knoll, L. Dean, William L. Furlow, Ralph C. Benson, & David L. Bilhartz. (1995). Management of Nondilatable Cavernous Fibrosis With the Use of a Downsized Inflatable Penile Prosthesis. The Journal of Urology. 153(2). 366–367. 40 indexed citations

11.

Austenfeld, Mark S., David L. Bilhartz, Ofer Nativ, George M. Farrow, & Michael M. Lieber. (1993). Flowcytometric DNA ploidy pattern for predicting metastasis of clinical stage I nonseminomatous germ cell testicular tumors. Urology. 41(4). 379–383. 7 indexed citations

12.

Stormont, Thomas J., David L. Bilhartz, & Horst Zincke. (1992). Pitfalls of “Bench Surgery” and Autotransplantation for Renal Cell Carcinoma. Mayo Clinic Proceedings. 67(7). 621–628. 18 indexed citations

13.

Montgomery, Benjamin T., Charles Y.F. Young, David L. Bilhartz, et al.. (1992). Hormonal regulation of prostate‐specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP. The Prostate. 21(1). 63–73. 163 indexed citations

14.

Bilhartz, David L., Donald J. Tindall, & Joseph E. Oesterling. (1991). Prostate-specific antigen and prosttic acid phosphatase: Biomolecular and physiologic characteristics. Urology. 38(2). 95–102. 33 indexed citations

15.

Young, Charles Y.F., et al.. (1991). Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP.. PubMed. 51(14). 3748–52. 235 indexed citations

16.

Bilhartz, David L., et al.. (1991). Prostate Specific Antigen in Hormonally Treated Stage D2 Prostate Cancer: Is it always an Accurate Indicator of Disease Status?. The Journal of Urology. 145(4). 802–806. 111 indexed citations

17.

He, Wei, Leslie M. Fischer, Siquan Sun, et al.. (1990). Molecular cloning of androgen receptors from divergent species with a polymerase chain reaction technique: Complete cDNA sequence of the mouse androgen receptor and isolation of androgen recepter cDNA probes from dog, guinea pig and clawed frog. Biochemical and Biophysical Research Communications. 171(2). 697–704. 76 indexed citations

18.

Qiu, Shu-Dong, Charles Y.F. Young, David L. Bilhartz, et al.. (1990). In Situ Hybridization of Prostate-Specific Antigen mRNA in Human Prostate. The Journal of Urology. 144(6). 1550–1556. 88 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact